Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zura Bio Limited - Class A Ordinary shares (NQ:ZURA)

1.515 +0.110 (+7.83%)
Delayed Quote Updated: 11:52 AM EST, Nov 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Zura Bio Limited - Class A Ordinary shares

< Previous 1 2 3 Next >
US Session Top Movers: FISN, XHLD, TLS Lead Gainers; ZURA, SOC, PLCE Lead Losers ↗
Via Chartmill
Top Movers Today: MF Gains 89.56%, ZURA Falls 72.98% ↗
Via Chartmill
US Gap-Up and Gap-Down Movers for the Nov. 9, 2026 Session ↗
Via Chartmill
Premarket Movers on Nov. 9, 2026: Small-Cap Gainers and Losers ↗
Via Chartmill
ZURA BIO LTD (NASDAQ:ZURA) Q1 2026: Cash Runway Extended Through 2028 as Phase 2 Trials Advance ↗
Via Chartmill
News headline image
ZURA Stock Earnings: Zura Bio Beats EPS for Q2 2024 ↗
ZURA stock results show that Zura Bio beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
These stocks have an unusual volume in today's session ↗
Via Chartmill
News headline image
Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio’s Lead Therapy ↗
William Blair starts Zura Bio (NASDAQ: ZURA) at Outperform, citing tibulizumab's multibillion-dollar potential in autoimmune disease. 
Via Benzinga
News headline image
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗
This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗
RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗
This clinical-stage biotech develops therapies targeting hematologic disorders, with a pipeline centered on red blood cell biology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Unusual volume stocks are being observed in Wednesday's session. ↗
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
News headline image
Here are the top movers in Tuesday's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
These stocks are moving in today's session ↗
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44.... 
Via Benzinga
News headline image
Top stock movements in today's session. ↗
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Wondering what's happening in today's pre-market session? ↗
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million. 
Via Benzinga
News headline image
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket ↗
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its... 
Via Benzinga
News headline image
Novartis Drug Shows Improvement In Sjögren's Disease In Late-Stage Trials: Analyst Deems Data Positive For Zura Bio As Well ↗
Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
ZURA Stock Earnings: Zura Bio Misses EPS for Q2 2024 ↗
ZURA stock results show that Zura Bio missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
3 Undervalued Biotech Stocks With Breakout Potential ↗
Invest in these three undervalued biotech stocks with double-digit upside ahead driven by cutting-edge healthcare advancements 
Via InvestorPlace
News headline image
The 3 Most Undervalued Biotech Stocks to Buy in July 2024 ↗
There’s always a strong case for undervalued biotech stocks especially with newer innovation and demand for better treatment. 
Via InvestorPlace
News headline image
3 Penny Stocks to Buy Now: May 2024 ↗
Penny stocks to buy carry a considerable amount of risk and extra sue dilligence is required before buying shares. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
ZURA Stock Earnings: Zura Bio Misses EPS for Q4 2023 ↗
ZURA stock results show that Zura Bio missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.